Special Feature
Pharm Exec's Emerging Pharma Leaders 2012
Meet our latest batch of Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history — by doing better with less while tapping new opportunities from science and technology to build competitive scale?...Read more
Regulatory
Comply or Die: GSK's New Corporate Integrity Agreement
Big Pharma talks a lot about the changing business model, but the fact remains that getting paid (and keeping investors happy) still depends on quantity of medicines sold. However, new provisions in corporate integrity agreements between government and pharma — GSK being the latest victim — could actually force companies to change their model, or pay the price ...Read More
Global
Can Emerging Markets Emerge Fast Enough?
The IMS Institute's annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy of Europe, Japan and the US?
...Read More
Communications
Pharma Surges Ahead in Online Communications
It may surprise some working in the industry, but pharmaceutical companies, particularly those based in Europe, are now ranking among the world's best online corporate communicators, according to a new report ...Read more
Washington Report
Who Will Pay for New Drugs?
Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. Jill Wechsler reports ...Read more
|
